<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prospective cohort studies of ZIKV infection during pregnancy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prospective cohort studies of ZIKV infection during pregnancy</h1>
<div class="graphic"><div class="figure"><div class="ttl">Prospective cohort studies of ZIKV infection during pregnancy</div><div class="cntnt"><table cellspacing="0"><colgroup span="7" width="14%"></colgroup> <tbody> <tr> <td class="subtitle1"> </td> <td class="subtitle1">Brasil et al, 2016<sup>[1]</sup><br/> Nielsen-Saines et al, 2019<sup>[2]</sup></td> <td class="subtitle1">Hoen et al, 2018<sup>[3]</sup></td> <td class="subtitle1">Pomar et al, 2018<sup>[4]</sup></td> <td class="subtitle1">Mulkey et al, 2019<sup>[5]</sup><br/> Mulkey et al, 2020<sup>[6]</sup></td> <td class="subtitle1">Ospina et al, 2020<sup>[7]</sup></td> <td class="subtitle1">Coutinho et al, 2020<sup>[8]</sup></td> </tr> <tr class="divider_bottom"> <td><strong>Site and recruitment period</strong></td> <td> <ul> <li>Rio de Janeiro, Brazil </li> <li>September 2015 to May 2016 </li> </ul> <p> </p> </td> <td> <ul> <li>French Guiana, Guadeloupe, and Martinique </li> <li>March 2016 to November 2016 </li> </ul> </td> <td> <ul> <li>French Guiana </li> <li>January 2016 to July 2016 </li> </ul> </td> <td> <ul> <li>Barranquilla, Colombia, and Washington, DC </li> <li>June 2016 to June 2017 </li> </ul> </td> <td> <ul> <li>Colombian national surveillance system </li> <li>June 2015 to July 2016 </li> </ul> </td> <td> <ul> <li>Ribeirão Preto, Brazil </li> <li>2015 to 2016 </li> </ul> </td> </tr> <tr class="divider_bottom"> <td><strong>Study design</strong></td> <td> <ul> <li>Longitudinal </li> </ul> </td> <td> <ul> <li>Longitudinal </li> </ul> </td> <td> <ul> <li>Longitudinal </li> </ul> </td> <td> <ul> <li>Longitudinal </li> </ul> </td> <td> <ul> <li>Surveillance data </li> </ul> </td> <td> <ul> <li>Longitudinal </li> </ul> </td> </tr> <tr class="divider_bottom"> <td><strong>Inclusion criteria for pregnant women</strong></td> <td> <ul> <li>Symptomatic ZIKV infection with rash confirmed by RT-PCR of blood or urine (rash with onset ≤5 days) </li> </ul> </td> <td> <ul> <li>Symptomatic ZIKV infection with at least one of the following confirmed by RT-PCR of blood or urine or both: rash, fever, conjunctivitis, arthralgia, or myalgia </li> </ul> </td> <td> <ul> <li>Symptomatic or asymptomatic ZIKV infection confirmed by RT-PCR in blood or urine or ZIKV IgM </li> </ul> </td> <td> <ul> <li>Symptomatic ZIKV infection with positive RT-PCR, IgM, IgG, or PRNT for ZIKV </li> </ul> </td> <td> <ul> <li>Symptomatic ZIKV infection with positive RT-PCR in serum </li> </ul> </td> <td> <ul> <li>Symptomatic ZIKV infection with positive RT-PCR of blood, urine, amniotic fluid, or placenta </li> </ul> </td> </tr> <tr class="divider_bottom"> <td><strong>Number of women with confirmed ZIKV infection in pregnancy</strong></td> <td> <ul> <li>244 </li> </ul> </td> <td> <ul> <li>561 </li> </ul> </td> <td> <ul> <li>498 </li> </ul> </td> <td> <ul> <li>82 </li> </ul> </td> <td> <ul> <li>5926* </li> </ul> </td> <td> <ul> <li>511 </li> </ul> </td> </tr> <tr class="divider_bottom"> <td><strong>Number of miscarriages/fetal losses</strong></td> <td> <ul> <li>10 (4.1%) </li> </ul> </td> <td> <ul> <li>28 (5.0%) </li> </ul> </td> <td> <ul> <li>32 (6.4%) </li> </ul> </td> <td> <ul> <li>2 (2.4%) </li> </ul> </td> <td> <ul> <li>172 (3.0%) </li> </ul> </td> <td> <ul> <li>24 (4.7%) </li> </ul> </td> </tr> <tr class="divider_bottom"> <td><strong>Loss to follow-up before or immediately after birth or excluded participants</strong></td> <td> <ul> <li>17 (7.0%) </li> </ul> </td> <td> <ul> <li>15 (2.7%) </li> </ul> </td> <td> <ul> <li>192 (38.6%) </li> </ul> </td> <td> <ul> <li>0 </li> </ul> </td> <td> <ul> <li>253 (4.3%) </li> </ul> </td> <td> <ul> <li>209 (42.7%) </li> </ul> </td> </tr> <tr class="divider_bottom"> <td><strong>Number of neonatal deaths</strong></td> <td> <ul> <li>1 (0.5%) </li> </ul> </td> <td> <ul> <li>Not reported </li> </ul> </td> <td> <ul> <li>Not reported </li> </ul> </td> <td> <ul> <li>1 (1.2%) </li> </ul> </td> <td> <ul> <li>48 (0.9%) </li> </ul> </td> <td> <ul> <li>2 (0.4%) </li> </ul> </td> </tr> <tr class="divider_bottom"> <td><strong>Number of infants with follow-up</strong></td> <td> <ul> <li>216 (88.5%) </li> </ul> </td> <td> <ul> <li>527 (93.9%) </li> </ul> </td> <td> <ul> <li>279 (56.0%) </li> </ul> </td> <td> <ul> <li>80 (97.5%) </li> </ul> </td> <td> <ul> <li>0 </li> </ul> </td> <td> <ul> <li>280 (57.3%) </li> </ul> </td> </tr> <tr class="divider_bottom"> <td><strong>Median infant follow-up time</strong></td> <td> <ul> <li>18 months (range 7 to 32 months) </li> </ul> </td> <td> <ul> <li>Birth </li> </ul> </td> <td> <ul> <li>3 days of life (range 0 to 7 days) </li> </ul> </td> <td> <ul> <li>18 months (range 4 to 18 months) </li> </ul> </td> <td> <ul> <li>Birth </li> </ul> </td> <td> <ul> <li>Birth (range 0 to 3 months) </li> </ul> </td> </tr> <tr class="divider_bottom"> <td><strong>Outcome measure</strong></td> <td> <ul> <li>Clinical abnormalities at birth and on follow-up </li> <li>Eye findings </li> <li>Hearing findings </li> <li>Neurodevelopment </li> </ul> </td> <td> <ul> <li>Clinical findings on the day of birth </li> </ul> </td> <td> <ul> <li>Clinical findings in the first week of life </li> </ul> </td> <td> <ul> <li>Neuroimaging findings </li> <li>Neurodevelopment </li> </ul> </td> <td> <ul> <li>Adverse pregnancy or neonatal outcome reported to surveillance system </li> </ul> </td> <td> <ul> <li>Pregnancy losses </li> <li>Abnormalities at birth to 3 months of age </li> </ul> </td> </tr> <tr class="divider_bottom"> <td><strong>Microcephaly</strong></td> <td> <ul> <li>8 (3.7%) </li> </ul> </td> <td> <ul> <li>32 (5.8%) </li> </ul> </td> <td> <ul> <li>31 (11.4%) of 273 infants </li> </ul> </td> <td> <ul> <li>3 (3.7%) </li> </ul> </td> <td> <ul> <li>93 (1.6%)<sup>¶</sup> </li> </ul> </td> <td> <ul> <li>16 (3.1%) </li> </ul> </td> </tr> <tr class="divider_bottom"> <td><strong>Small for gestational age</strong></td> <td> <ul> <li>10 (4.6%) </li> </ul> </td> <td> <ul> <li>53 (10%) </li> </ul> </td> <td> <ul> <li>26 (10.2%) of 255 infants </li> </ul> </td> <td> <ul> <li>Not reported </li> </ul> </td> <td> <ul> <li>333 (6.2%) </li> </ul> </td> <td> <ul> <li>45 (9.2%) </li> </ul> </td> </tr> <tr class="divider_bottom"> <td><strong>Preterm infants</strong></td> <td> <ul> <li>28 (13%) </li> </ul> </td> <td> <ul> <li>Not reported </li> </ul> </td> <td> <ul> <li>Not reported </li> </ul> </td> <td> <ul> <li>5 (6.3%) </li> </ul> </td> <td> <ul> <li>409 (7.5%) </li> </ul> </td> <td> <ul> <li>45 (9.2%) </li> </ul> </td> </tr> <tr class="divider_bottom"> <td><strong>Eye abnormalities on funduscopic examination</strong></td> <td> <ul> <li>128 examined (59.3%) and 9 (7%) had abnormalities </li> </ul> </td> <td> <ul> <li>39 with neurologic findings (7%) </li> </ul> </td> <td> <ul> <li>Not reported </li> </ul> </td> <td> <ul> <li>Not reported </li> </ul> </td> <td> <ul> <li>93 (1.6%)<sup>¶</sup> </li> </ul> </td> <td> <ul> <li>174 examined (35.6%) and 8 (4.6%) had abnormalities</li> </ul> </td> </tr> <tr class="divider_bottom"> <td><strong>Hearing abnormalities</strong></td> <td> <ul> <li>101 assessed (46.8%) and 13 (12%) had abnormalities </li> </ul> </td> <td> <ul> <li>Not reported </li> </ul> </td> <td> <ul> <li>Not reported </li> </ul> </td> <td> <ul> <li>Not reported </li> </ul> </td> <td> <ul> <li>Not reported </li> </ul> </td> <td> <ul> <li>261 assessed (53.4%) and 1 (0.4%) had an abnormality</li> </ul> </td> </tr> <tr class="divider_bottom"> <td><strong>Below average neurodevelopment</strong></td> <td> <ul> <li>Of 216 children evaluated, 62 (28.7%) had  below average neurodevelopment </li> </ul> </td> <td> <ul> <li>N/A </li> </ul> </td> <td> <ul> <li>N/A </li> </ul> </td> <td> <ul> <li>In 70 children evaluated, decline in neurodevelopment scores noted over time, 33% with abnormal findings </li> </ul> </td> <td> <ul> <li>N/A </li> </ul> </td> <td> <ul> <li>N/A </li> </ul> </td> </tr> <tr> <td><strong>Neurodevelopment tool</strong></td> <td> <ul> <li>Bayley-III </li> <li>Hammersmith Infant Neurological Examination </li> </ul> </td> <td> <ul> <li>N/A </li> </ul> </td> <td> <ul> <li>N/A </li> </ul> </td> <td> <ul> <li>Warner Initial Developmental Evaluation of Adaptive and Functional Skills (WIDEA) </li> <li>Alberta Infant Motor Scale (AIMS) </li> </ul> </td> <td> <ul> <li>N/A </li> </ul> </td> <td> <ul> <li>N/A </li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes">ZIKV: Zika virus; RT-PCR: reverse transcription polymerase chain reaction; IgM: immunoglobulin M; IgG: immunoglobulin G; PRNT: plaque reduction neutralization test; N/A: not available.<br/>* 45% of 18,117 pregnant women with symptoms of ZIKV infection tested; 33% of 18,117 positive by RT-PCR.<br/>¶ 1.6% for brain and eye defects combined. Individual microcephaly frequencies or individual eye abnormalities not reported. Eye abnormalities noted on physical inspection (not necessarily funduscopic evaluation).</div><div class="graphic_reference">References:

	<ol>
<li>Brasil P, Pereira JP Jr, Moreira ME, et al. Zika Virus Infection in Pregnant Women in Rio de Janeiro. N Engl J Med 2016; 375:2321.</li>
<li>Nielsen-Saines K, Brasil P, Kerin T, et al. Delayed childhood neurodevelopment and neurosensory alterations in the second year of life in a prospective cohort of ZIKV-exposed children. Nat Med 2019; 25:1213.</li>
<li>Hoen B, Schaub B, Funk AL, et al. Pregnancy Outcomes after ZIKV Infection in French Territories in the Americas. N Engl J Med 2018; 378:985.</li>
<li>Pomar L, Vouga M, Lambert V, et al. Maternal-fetal transmission and adverse perinatal outcomes in pregnant women infected with Zika virus: prospective cohort study in French Guiana. BMJ 2018; 363:k4431.</li>
<li>Mulkey SB, Bulas DI, Vezina G, et al. Sequential Neuroimaging of the Fetus and Newborn With In Utero Zika Virus Exposure. JAMA Pediatr 2019; 173:52.</li>
<li>Mulkey SB, Arroyave-Wessel M, Peyton C, et al. Neurodevelopmental Abnormalities in Children With In Utero Zika Virus Exposure Without Congenital Zika Syndrome. JAMA Pediatr 2020; 174:269.</li>
<li>Ospina ML, Tong VT, Gonzalez M, et al. Zika Virus Disease and Pregnancy Outcomes in Colombia. N Engl J Med 2020; 383:537.</li>
<li>Coutinho CM, Negrini S, Araujo D, et al. Early maternal Zika infection predicts severe neonatal neurological damage: results from the prospective Natural History of Zika Virus Infection in Gestation cohort study. BJOG 2020.</li>
</ol></div><div id="graphicVersion">Graphic 130633 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
